Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2002 Oct;93(10):1154–1163. doi: 10.1111/j.1349-7006.2002.tb01218.x

Development of Gene Therapy Using Prostate‐specific Membrane Antigen Promoter/Enhancer with Cre Recombinase/LoxP System for Prostate Cancer Cells under Androgen Ablation Condition

Shusei Ikegami 1, Takushi Tadakuma 2,✉, Satoshi Suzuki 1, Ichiro Yoshimura 1, Tomohiko Asano 1, Masamichi Hayakawa 1
PMCID: PMC5926883  PMID: 12417046

Abstract

To enhance the efficacy of suicide gene therapy for prostate cancer under androgen deprivation, we designed a promoter system that consists of the prostate‐specific membrane antigen (PSMA) promoter/enhancer (PEPM) and Cre‐loxP DNA recombination system. We constructed two kinds of plasmids. One plasmid contains a Cre recombinase (Cre) under the control of PEPM and the other expresses CMV‐lox‐luciferase/herpes simplex virus thymidine kinase (TK). In PSMA‐positive LNCaP cells, the promoter activity of the PEPM‐Cre plus CMV‐lox‐luciferase demonstrated 800‐fold greater activity compared with that of the PSMA promoter alone. However, no enhancement of the promoter activity was observed in the PSMA‐negative cells. Furthermore, in contrast to prostate specific antigen promoter/enhancer (PP), the promoter activity of PEPM did not decrease when the LNCaP cells were cultured in charcoal‐stripped fetal bovine serum (CFBS). In an in vitro gene therapy model with LNCaP cells, the cell growth inhibition in the presence of ganciclovir (GCV) was more evident in the cells transfected with the PEPM‐Cre plus CMV‐lox‐TK than in the cells with the PP‐TK, and the difference in efficacy between the two plasmids was more remarkable when the cells were maintained in CFBS medium. The therapeutic effect of PEPM‐Cre plus CMV‐lox‐TK was also observed in xenografted LNCaP cells on nude mice when the plasmids were directly injected into tumors and GCV was administered intraperitoneally. These findings indicate that the combination of the PSMA promoter/enhancer and the Cre‐loxP system can enhance the PSMA promoter activity even under androgen ablation conditions and can exert its anti‐tumor effect both in vitro and in vivo.

Keywords: Prostate specific membrane antigen, Cre loxP system, Prostate cancer, Androgen, Gene therapy

Full Text

The Full Text of this article is available as a PDF (679.7 KB).

REFERENCES

  • 1. ) Gotoh , A. , Ko , S. C , Shirakawa , T. , Cheon , J. , Kao , C. , Miyamoto , T. , Gardner , T. A. , Ho , L. J. , Cleutjens , C. B. J. , Trapman , J. , Graham , F. L. and Chung , L. W. K.Development of prostate‐specific antigen promoter‐based gene therapy for androgen‐independent human prostate cancer . J. Urol. , 160 , 220 – 229 ( 1998. ). [PubMed] [Google Scholar]
  • 2. ) Latham , J. P. F. , Searle , P. F. , Mautner , V. and James , N. D.Prostate‐specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue‐specific adenovirus vector . Cancer Res. , 60 , 334 – 341 ( 2000. ). [PubMed] [Google Scholar]
  • 3. ) Pang , S. , Dannull , J. , Kaboo , R. , Xie , Y. , Tso , C. L. , Michel , K. , Dekernion , J. B. and Belldegrun , A. S.Identification of a positive regulatory element responsible for tissue‐specific expression of prostate‐specific antigen . Cancer Res. , 57 , 495 – 499 ( 1997. ). [PubMed] [Google Scholar]
  • 4. ) Suzuki , S. , Tadakuma , T. , Asano T. and Hayakawa , M.Coexpression of the partial androgen receptor enhances the efficacy of prostate‐specific antigen promoter‐driven suicide gene therapy for prostate cancer cells at low testosterone concentrations . Cancer Res. , 61 , 1276 – 1279 ( 2001. ). [PubMed] [Google Scholar]
  • 5. ) Israeli , R. S. , Powell , C. T. , Fair , W. R. and Heston , W. D. W.Molecular cloning of a complementary DNA encoding a prostate‐specific membrane antigen . Cancer Res. , 53 , 227 – 230 ( 1993. ). [PubMed] [Google Scholar]
  • 6. ) Bostwick , D. G. , Pacelli , A. , Blute , M. , Roche , P. and Murphy , G. P.Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases . Cancer , 82 , 2256 – 2261 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Israeli , R. S. , Powell , C. T. , Corr , J. G. , Fair , W. R. and Heston , W. D. W.Expression of the prostate‐specific membrane antigen . Cancer Res. , 54 , 1807 – 1811 ( 1994. ). [PubMed] [Google Scholar]
  • 8. ) Silver , D. A. , Pellicer , L , Fair , W. R. , Heston , W. D. W. and Cordon‐Cardo , C.Prostate‐specific membrane antigen expression in normal and malignant human tissues . Clin. Cancer Res. , 3 , 81 – 85 ( 1997. ). [PubMed] [Google Scholar]
  • 9. ) Wright , G. L. , Jr. , Harley , C. , Beckett , M. L. and Schellhammer , P. F.Expression of prostate‐specific membrane antigen in normal, benign and malignant prostate tissues . Urol. Oncol. , 1 , 18 – 28 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Chang , S. S. , O'Keef , D. S. , Bacich , D. J. , Reuter , V. E. , Heston , W. D. W. and Gaudin , P. B.Prostate‐specific membrane antigen is produced in tumor‐associated neovas‐culature . Clin. Cancer Res. , 5 , 2674 – 2681 ( 1999. ). [PubMed] [Google Scholar]
  • 11. ) Kawasaki , M. and Nakayama , J.Enhanced expression of prostate‐specific membrane antigen gene in prostate cancer as revealed by in situ hybridization . Cancer Res. , 57 , 2321 – 2324 ( 1997. ). [PubMed] [Google Scholar]
  • 12. ) Wright , G. L. , Jr. , Grob , B. M. , Harley , C. , Grossman , K. , Newhall , K. , Petrylak , D. , Troyer , J. , Konchuba , A. , Schellhammer , P. F. and Moriatry , R.Upregulation of prostate‐specific membrane antigen after androgen‐deprivation therapy . Urology , 48 , 326 – 334 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Sternberg , N. and Hamilton , D.Bacteriophage P1 site‐specific recombination I. Recombination between loxP sites . J. Mol. Biol. , 150 , 467 – 486 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Sato , Y. , Tanaka , K. , Lee , G. , Kanegae , Y. , Sakai , Y. , Kaneko , S. , Nakabayashi , H. , Tamaoki , T. and Saito , I.Enhanced and specific gene expression via tissue‐specific production of Cre recombinase using adenovirus vector . Biochem. Biophys. Res. Commun. , 244 , 455 – 462 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Suzuki , S. , Tadakuma , T. , Kunitomi , T. , Takayama , E. , Sato , M. , Asano , T. , Nakamura , H. and Hayakawa , M.Liposome‐mediated gene therapy using HSV‐TK/ganciclovir under the control of human PSA promoter in prostate cancer cells . Urol. Int. , 67 , 216 – 223 ( 2001. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) O'Keef , D. S. , Su , S. L. , Bacich , D. J. , Horiguchi , Y. , Luo , Y. , Powell , C. T. , Zandvliet , D. , Russell , P. J. , Molloy , P. L. , Nowak , N. J. , Shows , T. B. , Mullins , C. , Vonder Haar , R. A. , Fair , W. R. and Heston , W. D. W.Mapping, genomic organization and promoter analysis of human prostate‐specific membrane antigen gene . Biochim. Biophys. Acta , 1443 , 113 – 117 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) O'Keef , D. S. , Uchida , A. , Bacich , D. J. , Watt , F. B. , Martorana , A. , Molly , P. L. and Heston , W. D. W.Prostate‐specific suicide gene therapy using the prostate‐specific membrane antigen promoter and enhancer . Prostate , 45 , 149 – 157 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Logan , J. J. , Bebok , Z. , Walker , L. C. , Peng , S. , Feigner , P. L. , Siegal , G. P. , Frizzell , R. A. , Dong , J. , Howard , M. , Matalon , S. , Lindsey , J. R. , Du Vail , M. and Sorscher , E. J.Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium . Gene Ther. , 2 , 38 – 49 ( 1995. ). [PubMed] [Google Scholar]
  • 19. ) Kunitomi , M. , Takayama , E. , Suzuki , S. , Yasuda , T. , Tsutsui , K. , Nagaike , K. , Hiroi , S. and Tadakuma , T.Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human α‐fetoprotein gene . Jpn. J. Cancer Res. , 91 , 343 – 350 ( 2000. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. ) Sugaya , S. , Fujita , K. , Kikuchi , A. , Ueda , H. , Takakuwa , K. , Kodama , S. and Tanaka , K.Inhibition of tumor growth by direct intratumoral gene transfer of herpes simplex virus thymidine kinase gene with DNA‐liposome complexes . Hum. Gene Ther. , 7 , 223 – 230 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Zou , Y. , Peng , H. , Zhou , B. , Wen , Y. , Wang , S. C. , Tsai , E. M. and Hung , M. C.Systemic tumor suppression by proapoptotic gene bik . Cancer Res. , 62 , 8 – 12 ( 2002. ). [PubMed] [Google Scholar]
  • 22. ) Gleave , M. , Hsieh , J. T. , Gao , C. , Von Eschenbach , A. C. and Chung , L. W. K.Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblasts . Cancer Res. , 51 , 3753 – 3761 ( 1991. ). [PubMed] [Google Scholar]
  • 23. ) Good , D. , Schwarzenberger , P. , Eastham , J. A. , Rhoads , R. E. , Hunt , J. D. , Collins , M. , Batzer , M. , Theodossiou , C. , Kolls , J. K. and Grimes , S. R.Cloning and characterization of the prostate‐specific membrane antigen promoter . J. Cell. Biochem. , 74 , 395 – 405 ( 1999. ). [PubMed] [Google Scholar]
  • 24. ) Uchida , A. , O'Keef , D. S. , Bacich , D. J. , Molloy , P. L. and Heston , W. D. W.In vivo suicide gene therapy model using a newly discovered prostate‐specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy . Urology , 58 , 132 – 139 ( 2001. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Gao , M. , Ossowski , L. and Ferrari , A. C.Activation of Rb and decline in androgen receptor protein precede retinoic acid‐induced apoptosis in androgen‐dependent LNCaP cells and their androgen‐independent derivative . J. Cell. Physiol. , 179 , 336 – 346 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Hall , S. J. , Mutchnik , S. E. , Yang , G. , Timme , T. L. , Nasu , Y. , Bangma , C. H. , Woo , S. L. , Shaker , M. and Thompson , T. C.Cooperative therapeutic effects of androgen ablation and adenovirus‐mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer . Cancer Gene Ther. , 6 , 54 – 63 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Marcelli , M. , Cunningham , G. R. , Walkup , M. , He , Z. , Sturgis , L. , Kagan , C. , Mannucci , R. , Nicoletti , L , Teng , B. and Denner , L.Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase‐7 as a new gene therapy strategy for prostate cancer . Cancer Res. , 59 , 382 – 390 ( 1999. ). [PubMed] [Google Scholar]
  • 28. ) Lockett , L. J. , Molloy , P. L. , Russell , P. J. and Both , G. W.Relative efficiency of tumor cell killing in vitro by two enzyme‐prodrug systems delivered by identical adenovirus vectors . Clin. Cancer Res. , 3 , 2075 – 2080 ( 1997. ). [PubMed] [Google Scholar]
  • 29. ) Brand , K. , Loser , P. , Arnold , W. , Bartels , T. and Strauss , M.Tumor cell‐specific transgene expression prevents liver toxicity of the adeno‐HSV/GCV approach . Gene Ther. , 5 , 1363 – 1371 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 30. ) Ichikawa , T. , Tamiya , T. , Adachi , Y. , Ono , Y. , Matsumoto , K. , Furuta , T. , Yoshida , Y. , Hamada , H. and Ohtomo , T.In vivo efficacy and toxicity of 5‐fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus . Cancer Gene Ther. , 7 , 73 – 82 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Maron , A. , Havaux , N. , Roux , A. , Knoops , B. , Perricaudet , M. and Octave , J. N.Differential toxicity of ganciclovir for rat neurons and astrocytes in primary culture following adenovirus‐mediated transfer of the HSV‐tk gene . Gene Ther. , 4 , 25 – 31 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Lehrman , S.Virus treatment questioned after gene therapy death . Nature , 401 , 517 – 518 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Hamel , W. , Magnelli , L. , Chiarugi , V. P. and Israel , M. A.Herpes simplex virus thymidine kinase/ganciclovir‐mediated apoptotic death of bystander cells . Cancer Res. , 56 , 2697 – 2702 ( 1996. ). [PubMed] [Google Scholar]
  • 34. ) Mesnil , M. , Piccoli , C. , Tiraby , G. , Willecke , K. and Yamasaki , H.Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins . Proc. Nad. Acad. Sci. USA , 93 , 1831 – 1835 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. ) Nomura , T. , Nakajima , S. , Kawabata , K. , Yamashita , F. , Takakura , Y. and Hashida , M.Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer . Cancer Res. , 57 , 2681 – 2686 ( 1997. ). [PubMed] [Google Scholar]
  • 36. ) Huber , B. E. , Austin , E. A. , Richards , C. A. and Davis , S. T.Metabolism of 5‐fluorocytosine to 5‐fluouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase . Proc. Nad. Acad. Sci. USA , 91 , 8302 – 8306 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. ) Takakuwa , K. , Fujita , K. , Kikuchi , A. , Sugaya , S. , Yahata , T. , Aida , H. , Kurabayashi , T. , Hasegawa , I. and Tanaka , K.Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA‐liposome complexes: growth inhibition of tumors and lack of localization in normal tissue . Jpn. J. Cancer Res. , 88 , 166 – 175 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. ) Chang , S. S. , Reuter , V. E. , Heston , W. D. W. , Bander , N. H. , Grauer , L. S. and Gaudine , P. B.Five different antiprostate‐specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor‐associated neovasculature . Cancer Res. , 59 , 3192 – 3198 ( 1999. ). [PubMed] [Google Scholar]
  • 39. ) Grauer , L. S. , Lawler , K. D. , Marignac , J. L. , Kumar , A. , Goel , A. S. and Wolfert , R. L.Identification, purification, and subcellular localization of prostate‐specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line . Cancer Res. , 58 , 4787 – 4789 ( 1998. ). [PubMed] [Google Scholar]
  • 40. ) Murphy , G. P. , Greene , T. G. , Tino , W. T. , Boynton , A. L. and Holmes , E. H.Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen . J. Urol. , 160 , 2396 – 2401 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 41. ) Smith‐Jones , P. M. , Vallabahajosula , S. , Goldsmith , S. J. , Navarro , V. , Hunter , C. J. , Bastidas , D. and Bander , N. H.In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate‐specific membrane antigen . Cancer Res. , 60 , 5237 – 5243 ( 2000. ). [PubMed] [Google Scholar]
  • 42. ) Ballangrud , Å. M. , Yang , W. H. , Charlton , D. E. , Mcdevitt , M. R. , Hamacher , K. A. , Panageas , K. S. , Ma , D. , Bander , N. H. , Scheinberg , D. A. and Sgouros , G.Response of LNCaP spheroids after treatment with an α‐particle emitter (213Bi)‐labeled anti‐prostate‐specific membrane antigen antibody (J591) . Cancer Res. , 61 , 2008 – 2014 ( 2001. ). [PubMed] [Google Scholar]
  • 43. ) Mcdevitt , M. R. , Barendswaard , E. , Ma , D. , Lai , L. , Curcio , M. J. , Sgouros , G. , Ballangrud , Å. M. , Yang , W. H. , Finn , R. D. , Pellegrini , V. , Greerlings , M. W. , Jr. , Lee , M. , Brechbiel , M. W. , Bander , N. H. , Cordon‐Cardo , C. and Scheinberg , D. A.An α‐particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer . Cancer Res. , 60 , 6095 – 6100 ( 2000. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES